HUE037423T2 - Szerin/treonin kináz inhibitorok - Google Patents

Szerin/treonin kináz inhibitorok

Info

Publication number
HUE037423T2
HUE037423T2 HUE13710222A HUE13710222A HUE037423T2 HU E037423 T2 HUE037423 T2 HU E037423T2 HU E13710222 A HUE13710222 A HU E13710222A HU E13710222 A HUE13710222 A HU E13710222A HU E037423 T2 HUE037423 T2 HU E037423T2
Authority
HU
Hungary
Prior art keywords
serine
kinase inhibitors
threonine kinase
threonine
inhibitors
Prior art date
Application number
HUE13710222A
Other languages
English (en)
Inventor
James F Blake
Mark Joseph Chicarelli
Rustam Ferdinand Garrey
John Gaudino
Jonas Grina
David A Moreno
Peter J Mohr
Li Ren
Jacob Schwarz
Huifen Chen
Kirk Robarge
Aihe Zhou
Original Assignee
Array Biopharma Inc
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Array Biopharma Inc, Genentech Inc filed Critical Array Biopharma Inc
Publication of HUE037423T2 publication Critical patent/HUE037423T2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
HUE13710222A 2012-03-01 2013-03-01 Szerin/treonin kináz inhibitorok HUE037423T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261605523P 2012-03-01 2012-03-01

Publications (1)

Publication Number Publication Date
HUE037423T2 true HUE037423T2 (hu) 2018-08-28

Family

ID=47892024

Family Applications (2)

Application Number Title Priority Date Filing Date
HUE17207123A HUE053994T2 (hu) 2012-03-01 2013-03-01 Szerin/treonin kináz inhibitorok
HUE13710222A HUE037423T2 (hu) 2012-03-01 2013-03-01 Szerin/treonin kináz inhibitorok

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HUE17207123A HUE053994T2 (hu) 2012-03-01 2013-03-01 Szerin/treonin kináz inhibitorok

Country Status (36)

Country Link
US (4) US8697715B2 (hu)
EP (2) EP3321262B1 (hu)
JP (2) JP6068515B2 (hu)
KR (1) KR102093526B1 (hu)
CN (2) CN104507926B (hu)
AR (2) AR090220A1 (hu)
AU (1) AU2013225737B2 (hu)
BR (1) BR112014021634B1 (hu)
CA (1) CA2866086C (hu)
CL (1) CL2014002301A1 (hu)
CO (1) CO7081155A2 (hu)
CR (1) CR20140413A (hu)
CY (1) CY1120172T1 (hu)
DK (2) DK3321262T3 (hu)
ES (2) ES2857649T3 (hu)
HK (3) HK1204323A1 (hu)
HR (2) HRP20180591T1 (hu)
HU (2) HUE053994T2 (hu)
IL (2) IL234376A (hu)
LT (2) LT3321262T (hu)
MX (1) MX354675B (hu)
MY (1) MY191936A (hu)
NO (1) NO2945854T3 (hu)
NZ (1) NZ700314A (hu)
PE (1) PE20150666A1 (hu)
PH (3) PH12015501653A1 (hu)
PL (2) PL3321262T3 (hu)
PT (2) PT3321262T (hu)
RS (2) RS61500B1 (hu)
RU (1) RU2650501C2 (hu)
SG (1) SG11201405356QA (hu)
SI (2) SI2820009T1 (hu)
TW (1) TWI589569B (hu)
UA (1) UA116774C2 (hu)
WO (1) WO2013130976A1 (hu)
ZA (2) ZA201406688B (hu)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX339873B (es) 2011-02-28 2016-06-15 Genentech Inc Inhibidores de serina/treonina cinasa.
CN103958502B (zh) 2011-08-04 2016-02-10 阵列生物制药公司 作为丝氨酸/苏氨酸激酶抑制剂的喹唑啉化合物
ES2857649T3 (es) * 2012-03-01 2021-09-29 Array Biopharma Inc Inhibidores de serina/treonina cinasa
MX363118B (es) * 2012-05-03 2019-03-11 Genentech Inc Derivados de pirazol aminopirimidina como moduladores de cinasa 2 de repeticion rica en leucina (lrrk2).
AR092253A1 (es) 2012-08-27 2015-04-08 Array Biopharma Inc Inhibidores de serina/treonina cinasa
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
EP2909206A1 (en) 2012-10-16 2015-08-26 F. Hoffmann-La Roche AG Serine/threonine kinase inhibitors
WO2017156493A1 (en) 2016-03-11 2017-09-14 Denali Therapeutics Inc. Compounds, compositions, and methods
US9532987B2 (en) * 2013-09-05 2017-01-03 Genentech, Inc. Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases
CU24425B1 (es) 2013-11-01 2019-06-04 Novartis Ag Amino-heteroaril-benzamidas como inhibidores de cinasa
KR102359759B1 (ko) * 2013-12-06 2022-02-09 제넨테크, 인크. 세린/트레오닌 키나제 저해제
JP6642942B2 (ja) * 2013-12-30 2020-02-12 アレイ バイオファーマ、インコーポレイテッド セリン／トレオニンキナーゼ阻害剤
WO2015103133A1 (en) * 2013-12-30 2015-07-09 Genentech, Inc. Serine/threonine kinase inhibitors
CN110452216B (zh) 2014-04-02 2022-08-26 英特穆恩公司 抗纤维化吡啶酮类
EP3129025B1 (en) * 2014-04-09 2019-05-15 Genentech, Inc. Process for the manufacturing of medicaments
US9879029B2 (en) 2014-12-22 2018-01-30 Eli Lilly And Company ERK inhibitors
TWI704151B (zh) * 2014-12-22 2020-09-11 美商美國禮來大藥廠 Ｅｒｋ抑制劑
AU2015396809B2 (en) * 2015-06-03 2019-07-11 Js Innopharm (Shanghai) Ltd. Heterocyclic compounds for treating psoriasis
WO2016192063A1 (en) * 2015-06-03 2016-12-08 Changzhou Jiekai Pharmatech Co. Ltd Heterocyclic compounds as erk inhibitors
IL291017B2 (en) 2015-10-21 2023-11-01 Otsuka Pharma Co Ltd Benzolactam compounds as protein kinase inhibitors
WO2017070708A1 (en) * 2015-10-23 2017-04-27 Array Biopharma, Inc. 2-aryl- and 2-heteroaryl-substituted 2-pyridazin-3(2h)-one compounds as inhibitors of fgfr tyrosine kinases
EA038028B1 (ru) 2015-11-09 2021-06-24 Астразенека Аб Производные дигидроимидазопиразинона, применимые в лечении рака
US11214565B2 (en) 2015-11-20 2022-01-04 Denali Therapeutics Inc. Compound, compositions, and methods
CN109072311A (zh) 2016-04-15 2018-12-21 豪夫迈·罗氏有限公司 用于癌症的诊断和治疗方法
RS62868B1 (sr) 2016-06-16 2022-02-28 Denali Therapeutics Inc Pirimidin-2-ilamino-1h-pirazoli kao inhibitori lrrk2 za upotrebu u lečenju neurodegenerativnih poremećaja
GB201706327D0 (en) 2017-04-20 2017-06-07 Otsuka Pharma Co Ltd A pharmaceutical compound
WO2019037640A1 (en) * 2017-08-22 2019-02-28 Js Innopharm (Shanghai) Ltd HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS, COMPOSITIONS COMPRISING THE HETEROCYCLIC COMPOUND, AND METHODS OF USING THE SAME
AU2018329925A1 (en) 2017-09-08 2020-03-05 F. Hoffmann-La Roche Ag Diagnostic and therapeutic methods for cancer
EA202091293A1 (ru) 2017-11-24 2020-11-23 Новартис Аг Производные пиридинона и их применение в качестве селективных ингибиторов alk-2
US11286248B2 (en) * 2018-02-08 2022-03-29 Zhangzhou Pien Tze Huang Pharmaceutical Co., Ltd. Pyrazine-2(1H)-ketone compound acting as FGFR inhibitor
WO2019158579A1 (en) 2018-02-13 2019-08-22 Vib Vzw Targeting minimal residual disease in cancer with rxr antagonists
WO2019223632A1 (en) * 2018-05-22 2019-11-28 Js Innomed Holdings Ltd. Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof
TW202102511A (zh) * 2019-03-28 2021-01-16 大陸商江蘇恆瑞醫藥股份有限公司 噻吩并雜環類衍生物、其製備方法及其在醫藥上的應用
WO2020228817A1 (zh) * 2019-05-15 2020-11-19 南京明德新药研发有限公司 Erk抑制剂及其应用
CN114206883A (zh) 2019-08-02 2022-03-18 伟迈可生物有限公司 氧代吡啶稠环衍生物及包含该衍生物的药物组合物
WO2022100586A1 (zh) * 2020-11-11 2022-05-19 南京明德新药研发有限公司 一种含氧杂环丁烷的螺环类化合物的晶型、制备方法及其应用
CN115413669B (zh) * 2022-06-14 2024-03-15 湖南大学 激酶抑制剂及其组合剂在提高植物青枯病抗性中的应用

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5612340A (en) 1993-10-01 1997-03-18 Ciba-Geigy Corporation Pyrimidineamine derivatives and processes for the preparation thereof
ATE325113T1 (de) * 1993-10-01 2006-06-15 Novartis Pharma Gmbh Pharmacologisch wirksame pyrimidinderivate und verfahren zu deren herstellung
US5543523A (en) 1994-11-15 1996-08-06 Regents Of The University Of Minnesota Method and intermediates for the synthesis of korupensamines
HUP0001140A3 (en) 1996-12-05 2002-05-28 Amgen Inc Thousand Oaks Substituted pyrimidinone and pyridone compounds and methods of use
US6602872B1 (en) * 1999-12-13 2003-08-05 Merck & Co., Inc. Substituted pyridazines having cytokine inhibitory activity
EP1261327B1 (en) 2000-02-25 2005-04-27 F.Hoffmann-La Roche Ag Adenosine receptor modulators
ATE284712T1 (de) 2000-04-26 2005-01-15 Eisai Co Ltd Medizinische zusammensetzungen zur förderung der aktivierung der eingeweide
WO2001083448A2 (de) 2000-05-02 2001-11-08 Tietze Lutz F Neue prodrugs von 6-hydroxy-2,3-dihydro-1h-indolen, 5-hydroxy-1,2-dihydro-3h-pyrrolo[3,2-e]indolen und 5-hydroxy-1,2-dihydro-3h-benzo[e]indolen sowie von 6-hydroxy-1,2,3,4-tetrahydro-benzo[f]chinolin-derivaten für eine selektive krebstherapie
WO2002088079A2 (en) 2001-05-01 2002-11-07 Bristol-Myers Squibb Company Dual inhibitors of pde 7 and pde 4
WO2003030909A1 (en) 2001-09-25 2003-04-17 Bayer Pharmaceuticals Corporation 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer
TWI330183B (hu) * 2001-10-22 2010-09-11 Eisai R&D Man Co Ltd
WO2003057689A1 (en) * 2002-01-02 2003-07-17 Fujisawa Pharmaceutical Co., Ltd. Aminopyrimidine compounds, processes for their preparation and pharmaceutical compositions containing them
DE60330126D1 (de) * 2002-02-14 2009-12-31 Pharmacia Corp Substituierte pyridinone als modulatoren für p38 map kinase
CA2485166A1 (en) * 2002-05-21 2003-12-04 Amgen Inc. Substituted pyrimidinone and pyridinone compounds
GB0215676D0 (en) * 2002-07-05 2002-08-14 Novartis Ag Organic compounds
DE60330485D1 (de) 2002-07-15 2010-01-21 Merck & Co Inc Zur behandlung von diabetes
US20050014753A1 (en) 2003-04-04 2005-01-20 Irm Llc Novel compounds and compositions as protein kinase inhibitors
CL2004002050A1 (es) * 2003-08-13 2005-06-03 Pharmacia Corp Sa Organizada B Compuestos derivados de piridinonas sustituidas; su uso en el tratamiento de afecciones causadas o exacerbadas por actividad p38 map kinasa y/o tnf no regulada, tales como inflamaciones, tumores, sida y otros.
TW200533357A (en) 2004-01-08 2005-10-16 Millennium Pharm Inc 2-(amino-substituted)-4-aryl pyrimidines and related compounds useful for treating inflammatory diseases
ATE485824T1 (de) 2004-04-13 2010-11-15 Icagen Inc Polycyclische pyrimidine als kaliumionenkanal- modulatoren
US7429604B2 (en) * 2004-06-15 2008-09-30 Bristol Myers Squibb Company Six-membered heterocycles useful as serine protease inhibitors
CA2578122A1 (en) 2004-08-27 2006-03-02 Gpc Biotech Ag Pyrimidine derivatives
GB0420722D0 (en) * 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
GB0428514D0 (en) 2004-12-31 2005-02-09 Prosidion Ltd Compounds
CA2606288A1 (en) 2005-04-18 2006-10-26 Neurogen Corporation Subtituted heteroaryl cb1 antagonists
GT200600381A (es) 2005-08-25 2007-03-28 Compuestos organicos
US7572809B2 (en) 2005-12-19 2009-08-11 Hoffmann-La Roche Inc. Isoquinoline aminopyrazole derivatives
ES2353437T3 (es) 2006-02-16 2011-03-02 Schering Corporation Derivados de pirrolidina como inhibidores de erk.
US7998978B2 (en) 2006-05-01 2011-08-16 Pfizer Inc. Substituted 2-amino-fused heterocyclic compounds
DE102006035202A1 (de) 2006-07-29 2008-01-31 Lanxess Deutschland Gmbh Konservierungsmittel auf Basis von Carbonsäureanhydriden
ES2373587T3 (es) 2006-08-23 2012-02-06 Pfizer Products Inc. Compuestos de pirimidona como inhibidores de gsk-3.
WO2008039882A1 (en) 2006-09-30 2008-04-03 Sanofi-Aventis U.S. Llc A combination of niacin and a prostaglandin d2 receptor antagonist
JO2985B1 (ar) 2006-12-20 2016-09-05 Takeda Pharmaceuticals Co مثبطات كينازmapk/erk
AU2007336933A1 (en) 2006-12-22 2008-07-03 Novartis Ag Heteroaryl-heteroaryl compounds as CDK inhibitors for the treatment of cancer, inflammation and viral infections
BRPI0806853B1 (pt) 2007-02-01 2018-03-20 Janssen Sciences Ireland Uc Processos e intermediários para preparar um inibidor de protease macrocíclico de hcv
US8273759B2 (en) 2007-06-08 2012-09-25 Bayer Cropscience Ag Fungicide heterocyclyl-pyrimidinyl-amino derivatives
CA2698511C (en) 2007-09-04 2016-10-11 The Scripps Research Institute Substituted pyrimidinyl-amines as protein kinase inhibitors
WO2009061761A2 (en) 2007-11-06 2009-05-14 E. I. Du Pont De Nemours And Company Fungicidal heterocyclic amines
NZ587504A (en) 2008-02-21 2012-09-28 Merck Sharp & Dohme Benzopyrazole derivatives as ERK inhibitors
US20090246198A1 (en) 2008-03-31 2009-10-01 Takeda Pharmaceutical Company Limited Mapk/erk kinase inhibitors and methods of use thereof
AU2009264242A1 (en) 2008-06-27 2009-12-30 Novartis Ag Organic compounds
KR20110025224A (ko) 2008-06-27 2011-03-09 아빌라 테라퓨틱스, 인크. 헤테로아릴 화합물 및 이의 용도
EP2370413B1 (en) * 2008-12-08 2015-08-05 Arena Pharmaceuticals, Inc. Modulators of the prostacyclin (pgi2) receptor useful for the treatment of disorders related thereto
DE102009051799B4 (de) 2009-11-03 2021-07-01 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts Bifunktionale Prodrugs und Drugs
DE102009060175A1 (de) 2009-12-23 2011-06-30 Merck Patent GmbH, 64293 Pyrrolo[2,3-d] pyrazin-7-yl-pyrimidin-Verbindungen
WO2012020786A1 (ja) * 2010-08-11 2012-02-16 日本新薬株式会社 医薬組成物
MX339873B (es) 2011-02-28 2016-06-15 Genentech Inc Inhibidores de serina/treonina cinasa.
CN102250065B (zh) * 2011-05-20 2015-05-13 浙江海正药业股份有限公司 取代的三嗪苯脲衍生物及其用途
CN103958502B (zh) 2011-08-04 2016-02-10 阵列生物制药公司 作为丝氨酸/苏氨酸激酶抑制剂的喹唑啉化合物
ES2857649T3 (es) * 2012-03-01 2021-09-29 Array Biopharma Inc Inhibidores de serina/treonina cinasa
AR092253A1 (es) 2012-08-27 2015-04-08 Array Biopharma Inc Inhibidores de serina/treonina cinasa
KR102244553B1 (ko) 2013-08-23 2021-04-23 가부시키가이샤 한도오따이 에네루기 켄큐쇼 용량 소자 및 반도체 장치
US9532987B2 (en) * 2013-09-05 2017-01-03 Genentech, Inc. Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases
JP6642942B2 (ja) * 2013-12-30 2020-02-12 アレイ バイオファーマ、インコーポレイテッド セリン／トレオニンキナーゼ阻害剤
WO2015103133A1 (en) * 2013-12-30 2015-07-09 Genentech, Inc. Serine/threonine kinase inhibitors
EP3129025B1 (en) * 2014-04-09 2019-05-15 Genentech, Inc. Process for the manufacturing of medicaments

Also Published As

Publication number Publication date
PH12015501653B1 (en) 2017-04-10
IL244276A0 (en) 2016-04-21
IL244276B (en) 2020-01-30
CN104507926A (zh) 2015-04-08
CO7081155A2 (es) 2014-10-10
NZ700314A (en) 2016-08-26
SG11201405356QA (en) 2014-11-27
DK2820009T3 (en) 2018-04-16
US9708290B2 (en) 2017-07-18
US20160122316A1 (en) 2016-05-05
KR20140138820A (ko) 2014-12-04
US10519126B2 (en) 2019-12-31
US8697715B2 (en) 2014-04-15
SI2820009T1 (en) 2018-05-31
JP2016027053A (ja) 2016-02-18
MX354675B (es) 2018-03-15
SI3321262T1 (sl) 2021-04-30
UA116774C2 (uk) 2018-05-10
RU2650501C2 (ru) 2018-04-16
ZA201406688B (en) 2017-08-30
ES2857649T3 (es) 2021-09-29
HK1206011A1 (en) 2015-12-31
PH12014501947B1 (en) 2014-11-24
PL2820009T3 (pl) 2018-09-28
US20140249127A1 (en) 2014-09-04
PH12015501653A1 (en) 2017-04-10
WO2013130976A1 (en) 2013-09-06
LT2820009T (lt) 2018-05-10
NO2945854T3 (hu) 2018-07-21
US20180127393A1 (en) 2018-05-10
RU2014139601A (ru) 2016-04-20
TW201339146A (zh) 2013-10-01
US20130252934A1 (en) 2013-09-26
ZA201508847B (en) 2023-01-25
US9259470B2 (en) 2016-02-16
BR112014021634A8 (pt) 2018-01-30
EP2820009A1 (en) 2015-01-07
PH12014501947A1 (en) 2014-11-24
PE20150666A1 (es) 2015-05-06
KR102093526B1 (ko) 2020-03-25
PH12015501654B1 (en) 2017-04-10
LT3321262T (lt) 2021-06-10
BR112014021634B1 (pt) 2022-09-27
PH12015501654A1 (en) 2017-04-10
JP6068515B2 (ja) 2017-01-25
CA2866086C (en) 2020-06-09
HK1204323A1 (en) 2015-11-13
HK1254429A1 (zh) 2019-07-19
CY1120172T1 (el) 2018-12-12
CR20140413A (es) 2014-11-05
AU2013225737B2 (en) 2018-03-01
CA2866086A1 (en) 2013-09-06
ES2665073T3 (es) 2018-04-24
DK3321262T3 (da) 2021-01-25
IL234376A (en) 2016-10-31
AR090220A1 (es) 2014-10-29
TWI589569B (zh) 2017-07-01
RS57097B1 (sr) 2018-06-29
PT3321262T (pt) 2021-03-04
AR121879A2 (es) 2022-07-20
RS61500B1 (sr) 2021-03-31
EP3321262B1 (en) 2021-01-13
CL2014002301A1 (es) 2015-05-08
CN104507926B (zh) 2016-08-31
PT2820009T (pt) 2018-04-12
CN106349217B (zh) 2020-08-28
HUE053994T2 (hu) 2021-08-30
CN106349217A (zh) 2017-01-25
HRP20180591T1 (hr) 2018-05-18
HRP20210482T1 (hr) 2021-05-14
PL3321262T3 (pl) 2021-06-28
JP2015508828A (ja) 2015-03-23
MX2014010432A (es) 2015-02-04
EP3321262A1 (en) 2018-05-16
EP2820009B1 (en) 2018-01-31
MY191936A (en) 2022-07-19

Similar Documents

Publication Publication Date Title
HK1254429A1 (zh) 絲氨酸/蘇氨酸激酶抑制劑
IL261282A (en) Furinone compounds as kinase inhibitors
HK1210775A1 (en) Imidazotriazinecarbonitriles useful as kinase inhibitors
HK1225735A1 (zh) 絲氨酸/蘇氨酸激酶抑制劑
HK1208442A1 (en) Substituted pyrrolopyrimidinylamino-benzothiazolones as mknk kinase inhibitors mknk
HK1223877A1 (zh) 絲氨酸/蘇氨酸激酶抑制劑
HK1210174A1 (en) Serine threonine kinase inhibitors for the treatment of hyperproliferativediseases
HK1222647A1 (zh) 激酶抑制劑
IL227399A0 (en) Novel azaindolylphenyl sulfonamides as serine/threonine kinase inhibitors
HUE048834T2 (hu) Kináz inhibitorok
HK1211574A1 (en) Serine threonine kinase inhibitors
HK1211578A1 (en) Amidoimidazopyridazines as mknk-1 kinase inhibitors mknk-1
GB201211310D0 (en) CSF-1R kinase inhibitors
EP2702064A4 (en) Kinase Inhibitors
ZA201604461B (en) Serine/threonine kinase inhibitors
PL2634185T3 (pl) Inhibitory kinazy TYK2
HK1199873A1 (en) Kinase inhibitors
HK1213252A1 (zh) 雙環二氫吡啶酮激酶抑制劑
SG11201500973WA (en) Amino-quinolines as kinase inhibitors
HK1213181A1 (zh) 雙環氧雜內酰胺激酶抑制劑